title: Effect of recombinant human thyroid-stimulating hormone or levothyroxine withdrawal on salivary gland dysfunction after radioactive iodine administration for thyroid remnant ablation.
abstract: The purpose of this study was to examine the incidence of sialadenitis and xerostomia within a year after radioactive iodine administration for thyroid remnant ablation after preparation with recombinant human thyroid-stimulating hormone (rhTSH) or levothyroxine (LT4 ) withdrawal.
  
  
  
  The study has included 121 patients, divided into 4 groups: group A (rhTSH = 100 mCi), group B (rhTSH = 70 mCi), group C (LT4 withdrawal = 100 mCi), and group D (LT4 withdrawal = 70 mCi). Study outcomes were Summated Xerostomia Inventory score and number of sialadenitis episodes after radioactive iodine administration.
  
  
  
  Salivary gland dysfunction was reported in 31% and 12% of patients, at the end of months 1 and 12, respectively. There was significantly lower incidence in groups A and B in comparison with groups C and D (p = .002 and .021, respectively).
  
  
  
  The use of rhTSH for preparation of radioactive iodine ablation as opposed to LT4 withdrawal reduces the incidence of salivary gland dysfunction. © 2015 Wiley Periodicals, Inc. Head Neck 38: E227-E230, 2016.
authors.affiliation: Third Department of Nuclear Medicine, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece.
authors.forename: Ioannis
authors.initials: I
authors.lastname: Iakovou
authors.affiliation: Unit of Reproductive Endocrinology, First Department of Obstetrics and Gynecology, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece.
authors.forename: Dimitrios G
authors.initials: DG
authors.lastname: Goulis
authors.affiliation: Second Department of Ear-Nose-Laryngology, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece.
authors.forename: Zinovia
authors.initials: Z
authors.lastname: Tsinaslanidou
authors.affiliation: Third Department of Nuclear Medicine, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece.
authors.forename: Evanthia
authors.initials: E
authors.lastname: Giannoula
authors.affiliation: Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece.
authors.forename: Grammatiki
authors.initials: G
authors.lastname: Katsikaki
authors.affiliation: Second Department of Ear-Nose-Laryngology, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece.
authors.forename: Iordanis
authors.initials: I
authors.lastname: Konstantinidis
mesh_terms: D000328:Adult; D005260:Female; D006801:Humans; D007457:Iodine Radioisotopes / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins / Q000627:therapeutic use; D012469:Salivary Glands / Q000503:physiopathology*; D012793:Sialadenitis / Q000139:chemically induced*; D013964:Thyroid Neoplasms / Q000532:radiotherapy / Q000601:surgery; D013972:Thyrotropin / Q000627:therapeutic use*; D013974:Thyroxine / Q000627:therapeutic use*; D016896:Treatment Outcome; D014987:Xerostomia / Q000139:chemically induced*
chemical_list: D007457:Iodine Radioisotopes; D011994:Recombinant Proteins; D013972:Thyrotropin; D013974:Thyroxine
keywords: 131-iodine ablation; levothyroxine withdrawal; recombinant human thyroid-stimulating hormone; sialadenitis; thyroid cancer